title: The antioxidant conundrum in cancer.
abstract: The health-related effects of interactions between reactive oxygen species (ROS) and dietary antioxidants and the consequences of dietary antioxidant supplementation on human health are by no means clear. Although ROS, normal byproducts of aerobic metabolism, are essential for various defense mechanisms in most cells, they can also cause oxidative damage to DNA, proteins, and lipids, resulting in enhanced disease risk. Dietary antioxidants (e.g., vitamin E, vitamin C, beta-carotene, and selenium), as well as endogenous antioxidant mechanisms, can help maintain an appropriate balance between the desirable and undesirable cellular effects of ROS. However, any health-related effects of interactions between dietary antioxidants and ROS likely depend on the health status of an individual and may also be influenced by genetic susceptibilities. Clinical studies of antioxidant supplementation and changes in either oxidative status, disease risk, or disease outcome have been carried out in healthy individuals, populations at risk for certain diseases, and patients undergoing disease therapy. The use of antioxidants during cancer therapy is currently a topic of heated debate because of an overall lack of clear research findings. Some data suggest antioxidants can ameliorate toxic side effects of therapy without affecting treatment efficacy, whereas other data suggest antioxidants interfere with radiotherapy or chemotherapy. Overall, examination of the evidence related to potential interactions between ROS and dietary antioxidants and effects on human health indicates that consuming dietary antioxidant supplements has pros and cons for any population and raises numerous questions, issues, and challenges that make this topic a fertile field for future research. Overall, current knowledge makes it premature to generalize and make specific recommendations about antioxidant usage for those at high risk for cancer or undergoing treatment.
authors.affiliation: Division of Cancer Prevention, National Cancer Institute/NIH, 6130 Executive Boulevard, Suite 3160, Bethesda, MD 20852, USA. hs41s@nih.gov
authors.forename: Harold E
authors.initials: HE
authors.lastname: Seifried
authors.forename: Sharon S
authors.initials: SS
authors.lastname: McDonald
authors.forename: Darrell E
authors.initials: DE
authors.lastname: Anderson
authors.forename: Peter
authors.initials: P
authors.lastname: Greenwald
authors.forename: John A
authors.initials: JA
authors.lastname: Milner
mesh_terms: D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D019587:Dietary Supplements / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D017382:Reactive Oxygen Species / Q000009:adverse effects / Q000378:metabolism
chemical_list: D000975:Antioxidants; D017382:Reactive Oxygen Species